title: Chloroquine-resistant Plasmodium vivax in Papua New Guinea.
abstract: An Australian expatriate on regular weekly antimalarial prophylaxis with chloroquine base and Maloprim developed symptomatic Plasmodium vivax infection which failed to respond adequately to 600 mg of chloroquine base. More ominously, a resident of the Highlands region of Papua New Guinea contracted vivax malaria which failed to be cleared by 2400 mg chloroquine base administered over 4 d. Both patients had achieved appropriate blood and plasma concentrations of chloroquine after treatment. Chloroquine-resistant P. vivax is now a clinical fact in Papua New Guinea.
authors.affiliation: Ok Tedi Mining Limited, Medical Department, Western Province, Papua New Guinea.
authors.forename: G J
authors.initials: GJ
authors.lastname: Schuurkamp
authors.forename: P E
authors.initials: PE
authors.lastname: Spicer
authors.forename: R K
authors.initials: RK
authors.lastname: Kereu
authors.forename: P K
authors.initials: PK
authors.lastname: Bulungol
authors.forename: K H
authors.initials: KH
authors.lastname: Rieckmann
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use; D002738:Chloroquine / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use; D004338:Drug Combinations; D004351:Drug Resistance; D006801:Humans; D016780:Malaria, Vivax / Q000188:drug therapy*; D008297:Male; D010219:Papua New Guinea; D010966:Plasmodium vivax / Q000187:drug effects; D011739:Pyrimethamine / Q000627:therapeutic use; D013413:Sulfadoxine / Q000627:therapeutic use
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; C001678:Maloprim; D013413:Sulfadoxine; D002738:Chloroquine; D003622:Dapsone; D011739:Pyrimethamine